TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36171584

Group type: EXPERIMENTAL
Intervention: Sports (Goalball, Football 5-a-side, Martial Arts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional training (Bodyweight exercises)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sports and functional training
Number of subjects: 0
Study: 32493441

Group type: EXPERIMENTAL
Intervention: Anakinra (100mg daily subcutaneous injection for up to 28 days)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Siltuximab (11mg/kg single intravenous injection)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8mg/kg single intravenous injection, max 800mg)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Anakinra and Siltuximab (combination treatment)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Anakinra and Tocilizumab (combination treatment)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 342
Study: 36018219

Group type: EXPERIMENTAL
Intervention: Test eldecalcitol soft capsules
Number of subjects: 58

Group type: COMPARATOR
Intervention: Reference eldecalcitol soft capsules
Number of subjects: 58
Study: 36318438

Group type: EXPERIMENTAL
Intervention: Yoga based Cardiac Rehabilitation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 80
Study: 33883411

Group type: EXPERIMENTAL
Intervention: 3D limb volume ultrasound combined with fetal abdominal circumference measurement
Number of subjects: 202

Group type: COMPARATOR
Intervention: Traditional formulas (Hadlock, Lee2009, INTERGROWTH-21st)
Number of subjects: 202
Study: 32672829

Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP) therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study: 36027496

Group type: EXPERIMENTAL
Intervention: KCl supplementation (24mmol thrice daily for 5 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 32950072

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 16703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16703
Study: 35279527

Group type: EXPERIMENTAL
Intervention: Durvalumab plus etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab plus etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805
Study: 33640203

Group type: EXPERIMENTAL
Intervention: Genetic enrichment analysis for ALS conditional on body mass index, body fat percentage, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and type 2 diabetes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of shared genetic loci between ALS and obesity-related traits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GGNBP2 identified as a novel ALS risk gene.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional enrichment analysis of shared risk genes.
Number of subjects: 0
Study: 32171877

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine digluconate (CHX)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 120

Group type: COMPARATOR
Intervention: MTA Fillapex
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (regardless of irrigation protocol and sealer)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laser therapies (PBT and PDT)
Number of subjects: 120
Study: 616173496

Group type: EXPERIMENTAL
Intervention: 1g/day n3-PUFA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4g/day n3-PUFA
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 34927469

Group type: EXPERIMENTAL
Intervention: Door-to-reperfusion time
Number of subjects: 2855

Group type: EXPERIMENTAL
Intervention: CTA-to-groin time
Number of subjects: 2855

Group type: EXPERIMENTAL
Intervention: Groin-to-reperfusion time
Number of subjects: 2855
Study: 32827656

Group type: EXPERIMENTAL
Intervention: Engaged in end-of-life discussions (EOLD)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Experience of caring for a loved one
Number of subjects: 836

Group type: COMPARATOR
Intervention: Experience of the death of a loved one
Number of subjects: 836
Study: 33092653

Group type: EXPERIMENTAL
Intervention: 40mg nanomicelles containing curcumin, four times per day for two weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsules with the same appearance and characteristics, four times per day for two weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40mg nanomicelles containing curcumin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 40
Study: 35239682

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 150
Study: 32387055

Group type: EXPERIMENTAL
Intervention: Ranibizumab (PRN dosing schedule)
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly dosing schedule)
Number of subjects: 943
Study: 36125830

Group type: EXPERIMENTAL
Intervention: High dose immunosuppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34388007

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy
Number of subjects: 144
Study: 35499570

Group type: EXPERIMENTAL
Intervention: Nonlinear Pedagogy (NLP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Linear Pedagogy (LP)
Number of subjects: 16
Study: 34797697

Group type: EXPERIMENTAL
Intervention: Oncologic home-hospitalization (OHH)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Full OHH
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Partial OHH
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard ambulatory cancer care (SOC)
Number of subjects: 148
Study: 32031651

Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation
Number of subjects: 7034

Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation (eligible participants)
Number of subjects: 7034

Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation (ineligible participants)
Number of subjects: 7034
Study: 35248268

Group type: EXPERIMENTAL
Intervention: Myofascial release (4 sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Electrotherapy (10 sessions)
Number of subjects: 32
Study: 34531304

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0
Study: 35351253

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study: 34245652

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Endometrial ablation (EA)
Number of subjects: 270
Study: 34750933

Group type: EXPERIMENTAL
Intervention: Triple therapy (NB-UVB, fractional CO2 laser, topical bimatoprost 0.01%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dual therapy (NB-UVB, fractional CO2 laser)
Number of subjects: 15
Study: 34501274

Group type: EXPERIMENTAL
Intervention: Active exercise program
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Exercise for well-being
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 35500968

Group type: EXPERIMENTAL
Intervention: Facilitatory kinesiology tape (applied from origin to insertion)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inhibitory kinesiology tape (applied from insertion to origin)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 32041744

Group type: EXPERIMENTAL
Intervention: Inulin supplementation in hum-ob mice on a high-fat diet
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Inulin supplementation in obese individuals
Number of subjects: 4
Study: 33530701

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention including facilitated conversation and advance directive completion
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group including Developmental/relationship history and Nutrition/Exercise
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 449
Study: 33127015

Group type: EXPERIMENTAL
Intervention: Immediate magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care with radiographs only
Number of subjects: 0
Study: 36112377

Group type: EXPERIMENTAL
Intervention: Self-cut mesh procedure
Number of subjects: 336

Group type: COMPARATOR
Intervention: Mesh-kit procedure
Number of subjects: 336
Study: 32384142

Group type: EXPERIMENTAL
Intervention: Test-Negative Design (TND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency-Matched Design (FMD)
Number of subjects: 0
Study: 33112245

Group type: EXPERIMENTAL
Intervention: Moderate interactivity (dropdown menus)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: High interactivity (dropdown menus and responsive infographics)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Control condition (no interactive features)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Moderate interactivity
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: High interactivity
Number of subjects: 983
Study: 35619813

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (LP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (LP) in pMMR subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 32178568

Group type: EXPERIMENTAL
Intervention: Sevoflurane-based combined intravenous and inhalation anesthesia (group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia (group P)
Number of subjects: 40
Study: 35561632

Group type: EXPERIMENTAL
Intervention: Negative emotionality (anxiety and depression symptoms, stress, negative affect)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Alcohol craving
Number of subjects: 73
Study: 34922494

Group type: EXPERIMENTAL
Intervention: Person-centred and health-promoting intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 81
Study: 35523498

Group type: EXPERIMENTAL
Intervention: High PEEP levels individually adjusted according to driving pressure in addition to RM
Number of subjects: 680

Group type: COMPARATOR
Intervention: Low PEEP levels (≤5 cm H2O) without RM
Number of subjects: 680
Study: 33588930

Group type: EXPERIMENTAL
Intervention: Visual method of oral hygiene education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Auditory method of oral hygiene education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Kinesthetic method of oral hygiene education
Number of subjects: 90
Study: 35319853

Group type: EXPERIMENTAL
Intervention: BASKA mask
Number of subjects: 65

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 65
Study: 35939599

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/day for 3 cycles)
Number of subjects: 323
Study: 34617505

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and well-being therapy (CBT/WBT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Clinical management (CM)
Number of subjects: 288
Study: 34380811

Group type: EXPERIMENTAL
Intervention: Customized obturator
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional obturator
Number of subjects: 48

Group type: COMPARATOR
Intervention: Without obturator
Number of subjects: 48
Study: 32176397

Group type: EXPERIMENTAL
Intervention: Years of education (measured by additional year of education)
Number of subjects: 1651
Study: 34973240

Group type: EXPERIMENTAL
Intervention: Combination group (tamsulosin (0.2 mg/day) plus mirabegron (50 mg/day))
Number of subjects: 218

Group type: COMPARATOR
Intervention: Tamsulosin‐alone group
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 218
Study: 34085479

Group type: EXPERIMENTAL
Intervention: Deep-tissue thread embedding therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Shallow-tissue thread embedding therapy
Number of subjects: 70
Study: 35109898

Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation with usual care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care alone (which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy)
Number of subjects: 320
Study: 34774052

Group type: EXPERIMENTAL
Intervention: Curcuma longa extract (CLE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32585907

Group type: EXPERIMENTAL
Intervention: Repeated Sprint Training (RST)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Repeated High-Intensity Technique Training (RTT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study: 36449671

Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted cataract surgery (FLACS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional phacoemulsification (CPS)
Number of subjects: 86
Study: 32143216

Group type: EXPERIMENTAL
Intervention: Navigational template
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 120
Study: 33302654

Group type: EXPERIMENTAL
Intervention: Internet plus graded diagnosis and treatment strategy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 36116480

Group type: EXPERIMENTAL
Intervention: 100 mg linzagolix per day alone
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 100 mg linzagolix per day with hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix per day alone
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix per day with hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study: 34032151

Group type: EXPERIMENTAL
Intervention: Yukgunja-Tang (YGJT) administered at 3.0 g twice a day for 4 weeks (total of 56 times)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yukgunja-Tang (YGJT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nutrition counseling
Number of subjects: 40
Study: 35379300

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 543
Study: 34069981

Group type: EXPERIMENTAL
Intervention: 4.0 g·d−1 β-alanine (BA) for four weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for four weeks
Number of subjects: 15
Study: 35342997

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily (QD) for 6 weeks
Number of subjects: 531

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily (QD) for 6 weeks
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg twice daily (BID) for 2 weeks followed by QD for 4 weeks
Number of subjects: 531

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg BID for 2 weeks followed by QD for 4 weeks
Number of subjects: 531
Study: 32970265

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35186107

Group type: EXPERIMENTAL
Intervention: Lianhua Qingke (LH) tablets (4 tablets, three times a day for 14 days)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (routine treatment without LH tablets)
Number of subjects: 144
Study: 35737911

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after autologous transplantation (ASCT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Observation after autologous transplantation (ASCT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MRD analysis using BM
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MRD analysis using PB
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Time‐varying kinetic model based on MRD results and Mantle Cell Lymphoma International Prognostic Index
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MRD as a predictor
Number of subjects: 300
Study: 33556032

Group type: EXPERIMENTAL
Intervention: MeCOVID (melatonin)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: EPICOS (tenofovir disoproxil/emtricitabine vs hydroxychloroquine vs combination therapy vs placebo)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 206
Study: 32503727

Group type: EXPERIMENTAL
Intervention: Regadenoson (A2AR agonist), continuous infusion starting at the time of skin incision, maximum dose of 1.44 µg/kg/min for 12 hours
Number of subjects: 14
Study: 35648046

Group type: EXPERIMENTAL
Intervention: Trauma-Integrated Mindfulness-Based Relapse Prevention (TI-MBRP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both TI-MBRP and MBRP
Number of subjects: 83
Study: 34256698

Group type: EXPERIMENTAL
Intervention: Individualized interventions delivered by the iCARE system (using comics, videos, pictures, text) in addition to standard care
Number of subjects: 2820

Group type: COMPARATOR
Intervention: Modified iCARE (only text) in addition to routine care
Number of subjects: 2820

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 2820
Study: 33837574

Group type: EXPERIMENTAL
Intervention: Soticlestat oral solution, single ascending doses up to 1350 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Soticlestat tablets under fed conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Soticlestat tablets under fasting conditions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36060668

Group type: EXPERIMENTAL
Intervention: TMS combined with CACT
Number of subjects: 86

Group type: COMPARATOR
Intervention: TMS
Number of subjects: 86
Study: 35126747

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between intervention and placebo groups
Number of subjects: 60
Study: 34655698

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 207946

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 207946

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 207946

Group type: COMPARATOR
Intervention: Other antidepressants (fluoxetine, paroxetine, escitalopram, citalopram, duloxetine, moclobemide, mirtazapine, bupropion)
Number of subjects: 207946
Study: 35617246

Group type: EXPERIMENTAL
Intervention: Cultural risk factors of suicide at Time 1
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Cultural stressors of suicide and depression
Number of subjects: 449
Study: 33231771

Group type: EXPERIMENTAL
Intervention: Standardized post-coercion review session
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 82
Study: 35800224

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol anesthesia with sinus rhythm (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol anesthesia with atrial fibrillation rhythm (group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with atrial fibrillation rhythm (group IV)
Number of subjects: 40
Study: 32045010

Group type: EXPERIMENTAL
Intervention: OSA patients without treatment
Number of subjects: 3978

Group type: EXPERIMENTAL
Intervention: OSA patients with treatment (continuous positive airway pressure or surgery)
Number of subjects: 3978

Group type: COMPARATOR
Intervention: Non-OSA patients
Number of subjects: 3978
Study: 33051276

Group type: EXPERIMENTAL
Intervention: Emergency treatment with Levetiracetam or Phenytoin
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Parent and practitioner support for EcLiPSE recruitment
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Research without prior consent processes
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Practitioner motivation and strong leadership
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Lack of leadership
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: EcLiPSE trial completion
Number of subjects: 143
Study: 32640554

Group type: EXPERIMENTAL
Intervention: Virtual Nature (VN) group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Virtual Abstract Painting (VAP) group
Number of subjects: 77
Study: 35487792

Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation (4,000 IU daily for 30 days)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 321
Study: 34098739

Group type: EXPERIMENTAL
Intervention: Twirla (2.3 mg ethinyl estradiol and 2.6 mg levonorgestrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twirla
Number of subjects: 0
Study: 35454330

Group type: EXPERIMENTAL
Intervention: Pedometer group (PG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study: 34465469

Group type: EXPERIMENTAL
Intervention: BIS 50 (light anaesthesia)
Number of subjects: 655

Group type: COMPARATOR
Intervention: BIS 35 (deep anaesthesia)
Number of subjects: 655
Study: 36352762

Group type: EXPERIMENTAL
Intervention: Tregopil 30 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tregopil 45 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Insulin Aspart (IAsp)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tregopil (combined group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tregopil
Number of subjects: 91
Study: 34134835

Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Avoidant class
Number of subjects: 200
Study: 32384397

Group type: EXPERIMENTAL
Intervention: Severe COVID-19 pneumonia
Number of subjects: 260
Study: 35028513

Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D supplementation (group A, n=120)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 2000 IU/day vitamin D supplementation (group B, n=115)
Number of subjects: 350

Group type: COMPARATOR
Intervention: 400 IU/day vitamin D supplementation (group C, n=115)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Comparison of serum 25(OH)D levels
Number of subjects: 350